+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Alexion Pharmaceuticals - logo

Alexion is a global biopharmaceutical company focused on developing and delivering life-transforming therapies for patients with devastating and rare diseases. Alexion developed Soliris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. Soliris is approved in more than 50 countries for PNH and more than 40 countries for aHUS. Alexion's company headquarters are based Cheshire, Connecticut, United States.

Sickle Cell Disease - Competitive landscape, 2023 - Product Thumbnail Image

Sickle Cell Disease - Competitive landscape, 2023

  • Report
  • May 2023
  • 196 Pages
  • Global
From
From
Mid-Size Pharmaceuticals Market Report 2025 - Product Thumbnail Image

Mid-Size Pharmaceuticals Market Report 2025

  • Report
  • February 2025
  • 200 Pages
  • Global
From
From
From
From
Dermatomyositis - Pipeline Insight, 2024 - Product Thumbnail Image

Dermatomyositis - Pipeline Insight, 2024

  • Clinical Trials
  • July 2024
  • 60 Pages
  • Global
From
Immunotherapy Drugs Market - Global Outlook & Forecast 2021-2026 - Product Thumbnail Image

Immunotherapy Drugs Market - Global Outlook & Forecast 2021-2026

  • Report
  • October 2021
  • 210 Pages
  • Global
From
From
Human Recombinant DNA: Global Markets - Product Thumbnail Image

Human Recombinant DNA: Global Markets

  • Report
  • July 2022
  • 84 Pages
  • Global
From
Acute Liver Failure - Pipeline Insight, 2024 - Product Thumbnail Image

Acute Liver Failure - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 40 Pages
  • Global
From
From
Lysosomal Disease Treatment Market Report 2025 - Product Thumbnail Image

Lysosomal Disease Treatment Market Report 2025

  • Report
  • February 2025
  • 200 Pages
  • Global
From
From
From
From
Loading Indicator